Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study

Methods. aEuro integral Fifty-two patients with hypogonadism and BPH were randomly assigned to receive testosterone (ART group) as 250 mg of testosterone enanthate every 4 weeks or to the untreated control group. We compared International Prostate Symptom Score (IPSS), uroflowmetry data, post-voiding residual volume (PVR) and systemic muscle volume at baseline and 12 months after treatment. Results. aEuro integral Forty-six patients (ART group, n aEuroS== aEuroS23; control, n aEuroS== aEuroS23) were included in the analysis. At the 12-month visit, IPSS showed a significant decrease compared with baseline in the ART group (15.7 aEuroS +/-+/- aEuroS8.7 vs. 12.5 aEuroS +/-+/- aEuroS9.5; p aEuroS < aEuroS0.05). No significant changes were observed in the control group. The ART group also showed improvement in maximum flow rate and voided volume (p aEuroS < aEuroS0.05), whereas no significant improvements were observed in the controls. PVR showed no significant changes in either group. In addition, the ART group showed significant enhancement of mean muscle volume (p aEuroS < aEuroS0.05), whereas no significant changes were seen in the controls. Conclusion. aEuro integral ART improved LUTS in hypogonadal men with mild BPH.